RUNX1–Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors

Authors :: Masamitsu Mikami
Tatsuya Masuda
Takuya Kanatani
Mina Noura
Katsutsugu Umeda
Hidefumi Hiramatsu
Hirohito Kubota
Tomoo Daifu
Atsushi Iwai
Etsuko Yamamoto Hattori
Kana Furuichi
Saho Takasaki
Sunao Tanaka
Yasuzumi Matsui
Hidemasa Matsuo
Masahiro Hirata
Tatsuki R. Kataoka
Tatsutoshi Nakahata
Yasumichi Kuwahara
Tomoko Iehara
Hajime Hosoi
Yoichi Imai
Junko Takita
Hiroshi Sugiyama
Souichi Adachi
Yasuhiko Kamikubo
Source :: Molecules and Cells. 45:886-895
Publication Year :: 2022
Publisher :: Korean Society for Molecular and Cellular Biology, 2022.
Abstract: Malignant rhabdoid tumor (MRT) is a highly aggressive pediatric malignancy with no effective therapy. Therefore, it is necessary to identify a target for the development of novel molecule-targeting therapeutic agents. In this study, we report the importance of the runt-related transcription factor 1 (

Subjects :: Base Sequence
Cell Line, Tumor
Survivin
Core Binding Factor Alpha 2 Subunit
Humans
Apoptosis
Cell Biology
General Medicine
Molecular Biology
Rhabdoid Tumor

Tools